TaiGen Biopharmaceuticals Holdings Limited (4157) Stock Statistics & Valuation Metrics

TaiGen Biopharmaceuticals Holdings Limited has a market cap or net worth of TWD 5.56B. The enterprise value is TWD 5.23B.

Market Cap

TWD 5.56B

Enterprise Value

TWD 5.23B

TaiGen Biopharmaceuticals Holdings Limited has 711,833,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

711,833,560

Owned by Insiders

―

Owned by Institutions

―

TaiGen Biopharmaceuticals Holdings Limited’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 4.85%.

Return on Equity (ROE)

0.04

Return on Assets (ROA)

0.04

Return on Invested Capital (ROIC)

4.85%

Return on Capital Employed (ROCE)

0.06

Revenue Per Employee

4.99M

Profits Per Employee

868.81K

Employee Count

52

Asset Turnover

0.22

Inventory Turnover

0.47

The current PE Ratio of TaiGen Biopharmaceuticals Holdings Limited is 37.24. TaiGen Biopharmaceuticals Holdings Limited’s PEG ratio is 0.05.

PE Ratio

37.24

PS Ratio

22.73

PB Ratio

5.68

Price to FCF

-76.28

Price to Operating Cash Flow

-78.96

PEG Ratio

0.05

In the last 12 months, TaiGen Biopharmaceuticals Holdings Limited had revenue of 259.47M and earned 45.18M in profits. Earnings per share was 0.06.

Revenue

259.47M

Gross Profit

223.83M

Operating Income

69.39M

Pretax Income

57.44M

Net Income

45.18M

EBITDA

86.87M

Earnings Per Share (EPS)

0.06

In the last 12 months, operating cash flow was -73.58M and capital expenditures -2.85M, giving a free cash flow of -76.42M billion.

Operating Cash Flow

-73.58M

Free Cash Flow

-76.42M

Free Cash Flow per Share

-0.11

TaiGen Biopharmaceuticals Holdings Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-1.32%

Earnings Yield

2.69%

Beta

0.54

52-Week Price Change

-14.18%

50-Day Moving Average

8.77

200-Day Moving Average

9.69

Relative Strength Index (RSI)

29.88

Average Volume (3m)

991.11K

TaiGen Biopharmaceuticals Holdings Limited upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 26, 2026

Next Earnings Date

Nov 18, 2026

Ex-Dividend Date

―

TaiGen Biopharmaceuticals Holdings Limited as a current ratio of 13.48, with Debt / Equity ratio of 4.58%

Current Ratio

13.48

Quick Ratio

12.56

Debt to Market Cap

0.00

Net Debt to EBITDA

-1.10

Interest Coverage Ratio

41.68

In the past 12 months, TaiGen Biopharmaceuticals Holdings Limited has paid 12.26M in taxes.

Income Tax

12.26M

Effective Tax Rate

0.21

TaiGen Biopharmaceuticals Holdings Limited EV to EBITDA ratio is 46.64, with an EV/FCF ratio of -73.84.

EV to Sales

22.01

EV to EBITDA

46.64

EV to Free Cash Flow

-73.84

EV to Operating Cash Flow

-76.70

TaiGen Biopharmaceuticals Holdings Limited has TWD 915.27M in cash and marketable securities with TWD 11.43M in debt, giving a net cash position of TWD 903.84M billion.

Cash & Marketable Securities

TWD 915.27M

Total Debt

TWD 11.43M

Net Cash

TWD 903.84M

Net Cash Per Share

TWD 1.27

Tangible Book Value Per Share

TWD 1.39

Gross margin is 92.05%, with operating margin of 32.24%, and net profit margin of 60.49%.

Gross Margin

92.05%

Operating Margin

32.24%

Pretax Margin

65.51%

Net Profit Margin

60.49%

EBITDA Margin

47.18%

EBIT Margin

42.83%

The average price target for TaiGen Biopharmaceuticals Holdings Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

530.40%

EPS Growth Forecast

―